EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Radiosurgery Before Surgery for the Treatment of Brain Metastases

Early Phase 1

Recruiting

Conditions: Metastatic Malignant Neoplasm in the Brain
Metastatic Malignant Solid Neoplasm

Interventions: Procedure: Resection
Drug: Dexamethasone
Radiation: Stereotactic Radiosurgery

First Posted Date: 2021-05-20

Last Posted Date: 2024-06-04

Lead Sponsor: Emory University

Target Recruit Count: 20

Registration Number: NCT04895592

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Early Phase 1

Recruiting

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: Duvelisib
Biological: Tisagenlecleucel

First Posted Date: 2021-05-18

Last Posted Date: 2023-10-13

Lead Sponsor: Emory University

Target Recruit Count: 20

Registration Number: NCT04890236

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

Phase 2

Recruiting

Conditions: Grade 2 Follicular Lymphoma
Marginal Zone Lymphoma
Grade 1 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Indolent Non-Hodgkin Lymphoma
Lymphoplasmacytic Lymphoma
Lymphoproliferative Disorder
Mantle Cell Lymphoma

Interventions: Drug: Acalabrutinib
Biological: Obinutuzumab
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-05-12

Last Posted Date: 2024-07-05

Lead Sponsor: Emory University

Target Recruit Count: 49

Registration Number: NCT04883437

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer

Phase 1

Recruiting

Conditions: Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
Unresectable Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma

Interventions: Drug: Cabozantinib S-malate
Drug: Enfortumab Vedotin
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-05-07

Last Posted Date: 2024-08-13

Lead Sponsor: Emory University

Target Recruit Count: 32

Registration Number: NCT04878029

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients

Phase 4

Recruiting

Conditions: Hyperglycemia Stress

Interventions: Device: Continuous glucose monitor (CGM), blinded
Drug: Placebo
Drug: Dulaglutide

First Posted Date: 2021-04-27

Last Posted Date: 2024-08-05

Lead Sponsor: Emory University

Target Recruit Count: 245

Registration Number: NCT04862234

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Grady Hospital, Atlanta, Georgia, United States

Combo-PEP: Multipurpose Prevention of Post-Exposure Prophylaxis Regimens

Phase 4

Completed

Conditions: Sexually Transmitted Diseases

Interventions: Drug: Doxycycline
Drug: Biktarvy

First Posted Date: 2021-04-27

Last Posted Date: 2023-05-23

Lead Sponsor: Emory University

Target Recruit Count: 20

Registration Number: NCT04860505

Locations: 🇺🇸
Hope Clinic, Atlanta, Georgia, United States

Remote Monitoring of COVID-19 Positive Outpatients

Terminated

Conditions: Covid19

Interventions: Other: Remote Monitoring of COVID-19

First Posted Date: 2021-04-21

Last Posted Date: 2023-06-18

Lead Sponsor: Emory University

Target Recruit Count: 300

Registration Number: NCT04853108

Locations: 🇺🇸
Emory Clinic, Emory University Hospital, Atlanta, Georgia, United States

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

Phase 2

Recruiting

Conditions: Locally Advanced Bladder Urothelial Carcinoma
Locally Advanced Renal Pelvis Urothelial Carcinoma
Locally Advanced Ureter Urothelial Carcinoma
Locally Advanced Urethral Urothelial Carcinoma
Locally Advanced Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Metastatic Urethral Urothelial Carcinoma
Metastatic Urothelial Carcinoma

Interventions: Drug: Pembrolizumab
Drug: Propranolol Hydrochloride
Drug: Nivolumab
Drug: Avelumab

First Posted Date: 2021-04-19

Last Posted Date: 2024-06-10

Lead Sponsor: Emory University

Target Recruit Count: 24

Registration Number: NCT04848519

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Community Trial in the Cherokee Nation

Not Applicable

Active, not recruiting

Conditions: Opioid Abuse

Interventions: Behavioral: Connect Program
Behavioral: Communities Mobilizing for Change and Action (CMCA)

First Posted Date: 2021-04-09

Last Posted Date: 2024-07-12

Lead Sponsor: Emory University

Target Recruit Count: 1152

Registration Number: NCT04839978

Locations: 🇺🇸
Cherokee Nation Reservation, Tahlequah, Oklahoma, United States

Cetirizine and Famotidine for COVID-19

Phase 4

Withdrawn

Conditions: Covid19

Interventions: Drug: Cetirizine and Famotidine
Drug: Placebo

First Posted Date: 2021-04-08

Last Posted Date: 2021-08-20

Lead Sponsor: Emory University

Registration Number: NCT04836806

Locations: 🇺🇸
Emory University Hospital at Wesley Woods COVID-19 Testing Facility, Atlanta, Georgia, United States
🇺🇸
Emory Healthcare Network Peachtree Immediate Care COVID-19 Testing Centers, Atlanta, Georgia, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy